Author

C. Hogea

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Abstract B060: Sociodemographic and geographic disparities in NCCN-concordant first-line systemic therapy in metastatic breast cancer, 2014–2022: The PRISM Study

Despite established NCCN guidelines, disparities in guideline-concordant care persist in metastatic breast cancer (mBC). We examined first-line Category 1 systemic therapy concordance and time to treatment to characterize equity gaps at an academic medical center. In the PRISM (Precision Oncology Risk Iden...

Drew Neish, T. Akinyemiju, Ashwini R. Joshi et al. · Cancer Epidemiology, Biomark... · 0 citations

Open access Sep 2026

Development and validation of CORe-MBC: a pragmatic measure of participatory care for adults with metastatic breast cancer

Introduction Existing research has linked increased patient participation in oncology care to greater patient satisfaction, enhanced quality of life, and improved healthcare utilization among patients with cancer. Yet, current measures of patient engagement and similar constructs do not reflect the unique experiences o...

Carolyn Hagler, S. Kircher, Guisselle A. Wismer et al. · Frontiers in Oncology · 0 citations

Review Open access Oct 2026

Real-World First-Line Treatment Characteristics and Physician Drivers in Advanced/Metastatic Non-Small Cell Lung Cancer, PD-L1 ≥ 50%, and without Actionable Genomic Alterations.

INTRODUCTION For patients with advanced/metastatic non-small cell lung cancer (aNSCLC) without actionable genomic alterations (AGAs) and with programmed death-ligand 1 (PD-L1) ≥ 50%, first-line (1L) treatment options include immunotherapy (IO) monotherapy or IO with chemotherapy. However, real-world data describing tre...

D. Owen, Martin Sebastian, H. Kenmotsu et al. · Oncology and Therapy · 0 citations